ForSight startup takes in $6M for advanced eye care
ForSight Vision4, the fourth vision technology startup incubated by ForSight Labs, has brought in $6 million in venture capital, reports VentureWire. While no investors in this recent round were named, the firm’s past companies have been backed by Morgenthaler Ventures, Split Rock Partners and Versant Ventures.
Based in Menlo Park, Calif., ForSight Labs has spun off four companies to date, each focusing on technology and devices used to provide advanced eye care. Its first company, glaucoma… Continue Reading
Life sciences briefing: Tuesday, Jan. 8, 2008
TODAY’S HEADLINES:
CyberHeart pumps in $9M for cardiac-arrhythmia treatment (release)
Incubator ForSight launches third device company with $6M funding (release)
Primera Biosystems raises $21M for molecular diagnostics (release)
Biogen Idec, PDL BioPharma take stakes in Ophthotech (release)
Technitrol acquires medical-device component maker Sonion for $385M (release)
DLJ Merchant Banking takes control of dentristy-product maker Den-Mat (release)
SV Life Sciences appoints Hamish Cameron as venture partner (release)
CyberHeart pumps in $9M for cardiac-arrhythmia treatment – CyberHeart, a Menlo Park, Calif., startup developing a non-invasive treatment… Continue Reading
Life sciences briefing: Tuesday, Oct. 9, 2007
Featured companies: AngioScore, Forsight Labs, Genoptix, Metastatix, Optherion, QLT
UPDATED: See below.
Artery opener AngioScore pulls in $30M — AngioScore, a Fremont, Calif., maker of balloon catheters used to open up clogged arteries, raised $30 million in a fifth funding round. Investors included Telegraph Hill Partners, Psilos Group Management, QuestMark Partners, L.P., UV Partners, California Technology Ventures and Innomed Ventures.
AngioScore’s balloon catheters, which inflate inside blocked blood vessels to restore blood flow, are designed to overcome problems that sometimes… Continue Reading
ForSight Labs appoints CEO, and invests $5M into second ophthalmic company
ForSight Labs, a Menlo Park, Ca. incubator of ophthalmic start-ups, said it has appointed K. Angela Macfarlane as President and CEO.
In addition, ForSight said it has invested in a second company. This company, name undisclosed, raised an initial $5 million round from Morgenthaler Ventures, Split Rock Partners and Versant Ventures, ForSight said in a statement.
Forsight Labs launches glaucoma treatment co., Transcend, with $7M
Medical incubator ForSight Labs has launched glaucoma treatment company, Transcend Medical, with a $7 million in a first round of funding from venture capitalists, according to VentureWire (sub required).
Morgenthaler Ventures and Split Rock Partners, two of the investors in ForSight, co-led the round. ForSight’s third investor, Versant Ventures, did not participate because it already has another glaucoma treatment company, Glaukos Corp., in its portfolio, Campbell told VentureWire. Morgenthaler, Split Rock and Versant participated in… Continue Reading